Table 2.
Part of clinical trials investigating combination of cancer vaccine with checkpoint inhibitors
| Agent | Malignance | Phase | Status/ results | NCT Identifier |
|---|---|---|---|---|
| GVAX+Nivolumab | Pancreatic cancer | I/II | Recruiting | NCT02451982 |
| DC AML Vaccine+CT-011 | Acute myelogenous leukemia | II | Recruiting | NCT01096602 |
| pTVG-HP Plasmid DNA Vaccine+ Pembrolizumab | Hormone-Resistant, Metastatic Prostate Cancer | I/II | Recruiting | NCT02499835 |
| DC Vaccines+ Nivolumab | Recurrent Grade III and Grade IV Brain Tumors | I | Recruiting | NCT02529072 |
| Provenge+ CT-011 | Advanced Prostate Cancer | II | Recruiting | NCT01420965 |
| GVAX+CRS207 With or Without Nivolumab | Metastatic Adenocarcinoma of the Pancreas | II | Recruiting | NCT02243371 |
| TLPLDC Vaccine+ checkpoint inhibitors | Metastatic Melanoma | I/II | Recruiting | NCT02678741 |
| Vigil™ vaccine+ Pembrolizumab | Advanced Melanoma | I | Recruiting | NCT02574533 |
| 6MHP+ Ipilimumab | Melanoma | I/II | Recruiting | NCT02385669 |
GVAX: Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Gene-transfected Tumor Cell Vaccine; DC: Dendritic Cell; AML: Acute Myelocytic Leukemia; CT-011: Pidilizumab, Pembrolizumab and Nivolumab, programmed cell death 1 blockade inhibitors; pTVG-HP: DNA vaccine encoding Prostatic acid phosphatase (PAP); CRS-207: live-attenuated Listeria vaccine expressing mesothelin; TLPLDC: tumor lysate particle-loaded dendritic cellvaccine; Vigil™: GMCSF/bi-shRNA furin DNA engineered autologous tumor cell product; 6MHP:six melanoma-associated helper peptides vaccine; Ipilimumab: cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody.